Malin Prenkert

Artiklar i tidskrifter

• Elvén, M. , Prenkert, M. , Holmström, I. K. & Edelbring, S. (2024). Reasoning about reasoning: using recall to unveil clinical reasoning in stroke rehabilitation teams. Disability and Rehabilitation.
• Ivarsson, M. , Prenkert, M. , Cheema, A. , Wretenberg, P. & Andjelkov, N. (2021). Mussel Adhesive Protein as a Promising Alternative to Fibrin for Scaffold Fixation during Cartilage Repair Surgery. Cartilage, 13 (Suppl. 2), 663S-671S.
• Prenkert, M. , Carlsson, E. , Svantesson, M. & Anderzén-Carlsson, A. (2017). Healthcare-professional patients’ conceptions of being ill and hospitalised: a phenomenographic study. Journal of Clinical Nursing, 26 (11-12), 1725-1736.
• Prenkert, M. & Ehnfors, M. (2016). Growth data of underprivileged children living in rural areas of Chin State, Burma/Myanmar, compared to the WHO reference growth standards: an observational study. BMJ Open, 6 (1).
• Svantesson, M. , Carlsson, E. , Prenkert, M. & Anderzen-Carlsson, A. (2016). 'Just so you know, the patient is staff': healthcare professionals' perceptions of caring for healthcare professional-patients. BMJ Open, 6 (1).
• Carlsson, E. , Anderzén Carlsson, A. , Prenkert, M. & Svantesson, M. (2016). Ways of understanding being a healthcare professional in the role of family member of a patient admitted to hospital: A phenomenographic study. International Journal of Nursing Studies, 53, 50-60.
• Prenkert, M. , Uggla, B. , Tidefelt, U. & Strid, H. (2010). CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells. Anticancer Research, 30 (10), 4157-61.
• Prenkert, M. , Uggla, B. , Tina, E. , Tidefelt, U. & Strid, H. (2009). Rapid Induction of P-Glycoprotein mRNA and Protein Expression by Cytarabine in HL-60 Cells. Anticancer Research, 29 (10), 4071-4076.
• Tina, E. , Prenkert, M. , Höglund, M. , Paul, C. & Tidefelt, U. (2009). Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C. Oncology Reports, 22 (6), 1527-1531.
• Möllgård, L. , Prenkert, M. , Smolowicz, A. , Paul, C. & Tidefelt, U. (2003). In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia . Leukemia and Lymphoma, 44 (5), 783-789.
• Tidefelt, U. , Prenkert, M. & Paul, C. (1996). Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Cancer Chemotherapy and Pharmacology, 38 (5), 476-480.

Doktorsavhandlingar, sammanläggningar

• Prenkert, M. (2010). On mechanisms of drug resistance in acute myeloid leukemia. (Doctoral dissertation). (Sammanläggning) Örebro: Örebro universitet.

Konferensbidrag

• Edelbring, S. , Elvén, M. , Holmström, I. K. & Prenkert, M. (2023). Person-Centeredness in Clinical Reasoning of Interprofessional Stroke Teams. I:  Patient Education and Counseling. Elsevier.
• Fransén, K. , Johansson, M. & Prenkert, M. (2016). Doktoranders upplevelse av nyttan med den obligatoriska forskarutbildningskursen Allmänvetenskaplig forskningsmetodik i medicinsk vetenskap vid Örebro universitet.  Konferensbidrag vid NU 2016, Malmö, Sweden, June 15-17, 2016.

Manuskript

• Prenkert, M. , Uggla, B. , Tidefelt, U. & Strid, H. CRIM1 is expressed at higher levels in drug resistant than in drug sensitive myeloid leukemia HL60 cells.